Report top-line data from the AURORA Phase 2 clinical study

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 31 Oct 2022
Due: 31 Dec 2023
Delivered: April 2024

Deadline
Met
Late
Not met
Today

What the company said

“AURORA study designed to assess changes in protoporphyrin IX levels, safety, tolerability, photosensitivity and other measures in a double-blind, placebo-controlled setting; top-line data expected in 2023”

SourceDisc Medicine, Inc. Form 8-K press release, 2022-10-31
FilingSEC filing index
Deadline as statedin 2023
Deadline used31 Dec 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2022-IRON-002117
Cite as https://keptindex.org/c/KI-C-2022-IRON-002117/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced an expectation to report top-line data from the AURORA study in 2023, but the data was not presented until April 2024.

A
Disc Medicine, Inc. 10-K filed 2024-03-21 Regulatory filing · published 21 Mar 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 106be8e176c3
“Topline data from AURORA is expected by March or April 2024.” ✓ confirmed on the page
A
Disc Medicine, Inc. 10-Q filed 2024-05-09 Regulatory filing · published 9 May 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 93ee97b0f3c8
“we presented topline data from AURORA in April 2024.” ✓ confirmed on the page

Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (20 Mar 2024 to 25 Mar 2024). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +121 days
2 versions

Version 1 · original · stated 31 Oct 2022

Deadline 31 Dec 2023 (“in 2023”) · wording expected
Version 2 · stated 21 Mar 2024

Deadline 30 Apr 2024 (“March / April 2024”) · wording expected

“Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: AURORA study top-line data
Where: United States
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.